Top of this page
Skip navigation, go straight to the content

Our Science Pipeline
 

R&D pipeline

 

The UCB pipeline delivers:

  •  a promising portfolio targeting severe diseases and addressing unmet medical needs
  •  focus on neurological and immunological diseases
  •  more convenient and effective treatments for patients and specialists.


UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

Small molecule drug / NCE

Small molecule drug / NCE

Antibody-based drug / NBE

Antibody-based drug / NBE



Neurology Indications Phase 1 Phase 2 Phase 3 Filed
padsevonil (PPSI)epilepsy – drug resistantphase 3 half
 epilepsy – drug resistantphase 2 three quarters
UCB0107 (Tau)Progressive Supranuclear Palsy (PSP)phase 1
UCB0599Parkinson's diseasephase 1 half
Immunology Indications Phase 1 Phase 2 Phase 3 Filed
bimekizumab (IL17AF)psoriasisphase 3
 psoriatic arthritisphase 3 half
 axial spondyloarthritis
phase 3 half
 hidradenitis suppurativa
phase 3 first quarter
rozanolixizumab (FcRn)myasthenia gravisphase 3 half
 immune thrombocytopeniaphase 3 first quarter
 chronic inflammatory demyelinating polyneuropathy (CIDP)phase 2 half
dapirolizumab pegol*systemic lupus erythematosusphase 2
UCB7858
auto-inflammatory diseasesphase 1 half

*

In collaboration with Biogen